Discriminating prevalent type 2 diabetes among community-dwelling older adults with metabolic dysfunction-associated steatotic liver disease: a comparative analysis of 12 insulin resistance surrogates - Summary - MDSpire
Advertisement
Discriminating prevalent type 2 diabetes among community-dwelling older adults with metabolic dysfunction-associated steatotic liver disease: a comparative analysis of 12 insulin resistance surrogates
To compare the associations and discriminatory ability of 12 surrogate insulin resistance indexes for prevalent type 2 diabetes mellitus among community-dwelling older adults with metabolic dysfunction-associated fatty liver disease.
Approach:
Study Design: Cross-sectional study based on a health examination cohort from a community in northwestern China.
Participants: 2641 eligible participants, including 605 older adults with metabolic dysfunction-associated steatotic liver disease.
Methods: Multivariable logistic regression, ROC curve analysis, RCS analysis, subgroup analysis, and exploratory internal model-discrimination analyses were performed.
Key Findings:
After multivariable adjustment, TyG, TyG-ABSI, TyG-WWI, and TyG-WC were significantly associated with prevalent T2DM (all P < 0.05).
TyG showed the highest discriminatory ability (AUC = 0.726, 95% CI: 0.686-0.766) with an optimal cut-off value of 9.225.
After Bonferroni correction, TyG performed significantly better than other indicators.
TyG remained the best-performing index even after excluding T2DM cases defined solely by fasting plasma glucose (AUC = 0.707).
Interpretation:
TyG and its variants are associated with prevalent T2DM and demonstrate moderate discriminatory ability in older adults with metabolic dysfunction-associated steatotic liver disease.
Limitations:
The study is cross-sectional, limiting causal inferences.
Data were extracted from routine health examination records, which may have inherent biases.
Conclusion:
TyG is a simple, integrated metabolic marker for identifying prevalent T2DM in older adults with metabolic dysfunction-associated fatty liver disease.